Ascendis Pharma A/S Ordinary Share (ASND)

Price$218.82

Value ScoreD

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-8.98%

Price vs S&P 500 (4W)-3.53%

VGM Score53.25

Market Capitalization$16.29B

All Metrics

P/CF (Annual)222.70x

Book Value / Share (Quarterly)$9.12

P/TBV (Annual)22.36x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)141.43%

Cash Flow / Share (Quarterly)$0.84

Price vs S&P 500 (YTD)-5.84%

Gross Margin (TTM)89.04%

Net Profit Margin (TTM)57.28%

EPS (TTM)$8.85

10-Day Avg Trading Volume0.56M

EPS Excl Extra (TTM)$8.85

Revenue Growth (5Y)152.98%

EPS (Annual)$-4.38

ROI (Annual)-75.57%

Gross Margin (Annual)86.82%

Net Profit Margin (5Y Avg)-1277.24%

Cash / Share (Quarterly)$10.70

P/E Basic Excl Extra (TTM)24.20x

Revenue Growth QoQ (YoY)144.27%

ROA (Last FY)-17.51%

Revenue Growth TTM (YoY)134.82%

EBITD / Share (TTM)$0.25

ROE (5Y Avg)-79.56%

Operating Margin (TTM)-0.84%

Cash Flow / Share (Annual)$0.85

P/B Ratio24.60x

P/B Ratio (Quarterly)24.94x

Net Income / Employee (Annual)$-223,509

EV / Revenue (TTM)14.24x

Net Interest Coverage (TTM)-1.78x

ROA (TTM)35.75%

EV / EBITDA (TTM)909.16x

EPS Incl Extra (Annual)$-4.38

Current Ratio (Annual)1.04x

Quick Ratio (Quarterly)0.68x

3-Month Avg Trading Volume0.69M

52-Week Price Return37.01%

EV / Free Cash Flow (Annual)271.44x

P/E Incl Extra (TTM)24.20x

Revenue / Employee (TTM)$848,588

Tangible BV / Share (Quarterly)$9.05

P/S Ratio (Annual)16.67x

Asset Turnover (Annual)0.55x

52-Week High$250.74

Operating Margin (5Y Avg)-1434.27%

EPS Excl Extra (Annual)$-4.38

CapEx CAGR (5Y)-17.01%

Tangible BV CAGR (5Y)7.07%

26-Week Price Return6.95%

Quick Ratio (Annual)0.72x

13-Week Price Return-2.13%

Total Debt / Equity (Annual)1.93x

Current Ratio (Quarterly)1.00x

Enterprise Value$14.36B

Revenue / Share Growth (5Y)144.03%

Asset Turnover (TTM)0.62x

Book Value / Share Growth (5Y)-1.87%

Revenue / Employee (Annual)$705,836

Inventory Turnover (Annual)0.32x

Pretax Margin (Annual)-29.53%

Cash / Share (Annual)$11.58

3-Month Return Std Dev38.83%

Gross Margin (5Y Avg)77.81%

Net Income / Employee (TTM)$486,056

ROE (Last FY)-221.49%

Net Interest Coverage (Annual)0.26x

EPS Basic Excl Extra (Annual)$-4.38

Receivables Turnover (TTM)7.06x

EV / Free Cash Flow (TTM)273.95x

Total Debt / Equity (Quarterly)1.84x

EPS Incl Extra (TTM)$8.85

Receivables Turnover (Annual)4.68x

ROI (TTM)45.45%

P/S Ratio (TTM)13.86x

Pretax Margin (5Y Avg)-1274.82%

Revenue / Share (Annual)$13.85

Tangible BV / Share (Annual)$5.34

Forward P/E15.45x

Price vs S&P 500 (52W)8.81%

P/E Ratio (TTM)24.20x

Year-to-Date Return5.10%

5-Day Price Return-9.29%

EPS Normalized (Annual)$-4.38

ROA (5Y Avg)-39.35%

Net Profit Margin (Annual)-31.67%

Month-to-Date Return-2.30%

Cash Flow / Share (TTM)$-13.25

EBITD / Share (Annual)$-2.21

Operating Margin (Annual)-18.92%

LT Debt / Equity (Annual)1.83x

P/CF (TTM)198.43x

ROI (5Y Avg)-48.05%

P/E Excl Extra (TTM)24.20x

LT Debt / Equity (Quarterly)0.79x

EPS Basic Excl Extra (TTM)$8.85

P/TBV (Quarterly)25.13x

P/B Ratio (Annual)22.25x

Inventory Turnover (TTM)0.31x

Pretax Margin (TTM)-19.32%

Book Value / Share (Annual)$5.36

Price vs S&P 500 (13W)-11.88%

Beta0.38x

P/FCF (Annual)264.30x

Revenue / Share (TTM)$15.64

ROE (TTM)128.97%

52-Week Low$158.16

vGradeD

gGradeA

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.90est. 0.24

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.42

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$218.82
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Ascendis Pharma is a biopharmaceutical company that develops therapeutics using its proprietary TransCon technology platform, with a pipeline focused on endocrinology and oncology indications including TransCon PTH and TransCon CNP. The company primarily generates revenue from the United States, with operations across Europe and international markets.